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Table 1. Comparison of PD versus no PD patient groups.
No PD (N=174)
PD
(N=102) p Value
BSA 1.750.23 1.850.24 <0.0001
Sex (male) 68/174 69/102 <0.0001
Sagittal Annulus 22.301.96 23.321.62 <0.0001
3D Perimeter 72.67.1 76.36.0 0.004
3D Area 410.981.2 451.268.4 0.007
Baseline EOA
indexed(cm2/m2)
0.360.11 0.380.15 0.30
Post TAVR EOA
indexed(cm2/m2)
1.100.22 1.120.019 0.517
Performance Index
3DE (Area)
0.470.07 (n¼87) 0.440.06 (n¼33) 0.046
Mean PVR* 1.130.39 1.550.75 <0.0001
Prosthesis-Patient
Mismatch
15/159 (9.4%) 5/98
(5%)
0.025
Cover Index 2DE (%) 10.34.4 7.73.8 <0.0001
Cover Index 3DE
Perimeter (%)
7.54.4 4.65.0 0.005
Cover Index 3DE
Area (%)
16.77.9 11.79.2 0.007
*PVR is treated as a continuous variable using the following grading scheme: 1¼none/trace,
2¼mild, 3¼moderate, 4¼severe
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Difference of Short Term Outcome in Low, Intermediate and High risk Patient in
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Background: Short term outcome of TAVI in intermediate and low risk patient is not
well known. We performed a cross sectional study to investigate short term mortality
and major cardiovascular event (MACE) in low and intermediate risk patients, and
compared to those in high risk patients.
Methods: Consecutive 125 patients who received TAVI were included in the study.
High, intermediate and low risk for surgical aortic valve replacement (S-AVR) was
deﬁned as STS score was 10 or higher, 4-9.99 and less than 4, respectively. MACE was
deﬁned as death, stroke, myocardial infarction, unplanned open chest or peripheral
vascular repair/intervention, acute kidney injury and lethal bleeding according to the
VARC deﬁnition. Odds ratios (ORs) of in hospital mortality andMACE in intermediate
and low risk patients compared to high risk patients were calculated with multivariate
logistic regression analysis adjusted for patient background.
Results: 35, 70 and 20 patients were included in high, intermediate and low risk
group. Mortality was observed in 3 (8.6%), 2 (2.9%) and 0 (0%) patients and mortality
rate in each risk group was same or lower than bottom level of STS score deﬁned in
each risk stratiﬁcation (10%, 4% and 0%). MACE was observed in 14 (40.0%), 12
(17.1%) and 2 (10.0%) patients. ORs of mortality in intermediate and low risk group
were 0.53 (95%CI: 0.02-12.3, p ¼ 0.70) and <0.55 (95%CI: 0.00-0.00, p < 0.23).
ORs of MACE were 0.27 (95% CI: 0.10-0.74, p ¼ 0.011) and 0.27 (95% CI: 0.05-
1.54, p ¼ 0.14). No signiﬁcant difference in mortality and MACE between interme-
diate and low risk group (p ¼ 1.00 and p ¼ 0.73, respectively).
Conclusions: Compared to surgical risk, mortality rate was lower especially in high
and intermediate risk group in TAVI. Compared to high risk patients, intermediate and
low risk patients showed lower risk for in hospital mortality and MACE although
difference did not reach statistical signiﬁcance due to lack of sample size. Intermediate
and low risk patients showed similar short term outcome after TAVI. Result of the
study indicated a possibility that TAVI is effective especially for intermediate risk
patient for S-AVR.
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Clinical Outcomes of Patients With Low Flow, Low Gradient Severe Aortic
Stenosis According To Treatment Modality
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Background: The aim of this study was to assess the role of transcatheter aortic valve
implantation (TAVI) compared with medical treatment (MT) and surgical aortic valve
replacement (SAVR) in patients presenting with low-ﬂow, low-gradient (LFLG)
severe aortic stenosis (AS).
Methods: Between 2006 and 2012, 142 patients with LFLG severe AS (indexed
aortic valve area [AVAi] 0.6cm2.m-2, ejection fraction [EF] <50% and mean
gradient [MG] <40mmHg) and a complete pre-TAVI right and left heart catheteri-
zation underwent treatment allocation to MT (n¼28) SAVR (n¼41) or TAVI (n¼73).
Results: Baseline characteristics were similar among patients allocated to MT and
TAVI, whereas patients allocated to SAVR were younger (MT 82.05.2 vs SAVR
75.75.6 vs TAVI 82.24.8 years, p<0.0001) and were at lower predicted surgical risk
(Logistic EuroSCORE MT 39.114.1 vs SAVR 20.713.6 vs TAVI 35.715.2%).
Pre-procedural invasive hemodynamic indices were similar among MT and TAVI
patients, whereas patients allocated to SAVR had a higher MG (p¼0.03) and EF
(p¼0.008) and lower pulmonary artery (PA) systolic (p<0.0001) pressures. OverallMG
was 26.48.4 mmHg, mean AVAi was 0.330.12, mean systemic vascular resistance
was 2071.9701.0 dyne.s.cm-2,mean PApressurewas 36.710.8mmHg andmean EF
was 33.08.8 %. All-cause mortality at 30-days was similar among SAVR (4.9%) and
TAVI (5.5%) patients, but was non-signiﬁcantly higher among MT patients (17.9%,
p¼0.08). Unadjusted rates of all-cause mortality at 12 months were signiﬁcantly lower
for SAVR (17.1%) and TAVI (17.8%) as comparedwithMT (42.9%, p¼0.02). Adjusted
hazard ratios for death were 0.39 (95% conﬁdence interval: 0.16 to 0.94) for SAVR
compared withMT and 0.35 (95% conﬁdence interval: 0.17 to 0.70) for TAVI compared
with MT. Medical treatment (p¼0.02) and pulmonary hypertension (p¼0.03) were
signiﬁcantly associated with all-cause mortality at 12 months on multivariate analysis.
Conclusions: Among patients with low-ﬂow, low-gradient severe AS, SAVR and
TAVI improved survival compared with MT. Clinical outcomes of TAVI and SAVR
appeared similar among appropriately selected patients with LFLG severe AS.
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Background: There is a trend for use of advanced adjunctive technology to support
trans-catheter aortic valve implantation. It is not clear whether this approach is
superior to a minimalist approach.
Methods: We assessed in-hospital MACE, 30-day and 1 year clinical outcomes
among patients undergoing TAVI employing a less intensive assessment and
performance protocol, using registry data from two UK TAVI centres. Mortality
tracking was reported as of December 2012.
Results: Within the study cohort (n¼384) mean age was 81.47.0 years and 46.3%
were male. Logistic EuroSCORE was 19.211.6. Mean peak aortic valve gradient
and aortic valve area were 79.725.2mmHg and 0.620.20cm2 respectively. Aortic
annular size was assessed by transthoracic echo (TTE; 73.4%), transoesophageal echo
(TOE; 24.5%) and multislice computerised tomography (MSCT; 0.5%). Mean aortic
annular diameter was 23.12.4mm. Pre-procedural iliofemoral assessment was by
invasive contrast angiography (99.5%) or MSCT (0.5%). Procedures were performed
under local anaesthetic alone (39.1%), local anaesthetic and anaesthetic sedation
(46.0%), or general anaesthesia (14.9%). Device implantation was predominantly with
the CoreValve self-expanding prosthesis (87.7%) and via the femoral approach
(90.7%). Device implantation employed contrast aortography in all cases with
supportive TTE (85%), TOE (3.4%), or no additional imaging (11.6%). Procedural
success was 96.1%. Procedural complications included death (0.8%) and valve-in-
valve implantation (3.1%). Overall in-hospital MACE was 6.0%. Aortic regurgitation
grade2 was seen in 12.5%. Mortality rates were in-hospital 3.5%, 30-day 5.5% and
one-year 15.2%.
Conclusions: Excellent TAVI clinical outcomes can be achieved despite limited use
of computerised tomography, transoesophageal echocardiography and general
anaesthesia.acts/POSTER/Aortic Valve Disease and Treatment B217
